US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Definium Therapeutics

38.23

-0.2700-0.70%

Volume:416.43K

Turnover:16.22M

Market Cap:5.14B

PE:-10.98

High:40.07

Open:38.50

Low:38.17

Close:38.50

52wk High:49.70

52wk Low:8.70

Shares:134.37M

Float Shares:131.11M

Volume Ratio:0.72

T/O Rate:0.32%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.4823

EPS(LYR):-2.0600

ROE:-64.09%

ROA:-20.64%

PB:5.59

PE(LYR):-18.56

Loading ...

Overview Company News Filings

Definium Therapeutics price target raised to $57 from $37 at Baird

U.S. RESEARCH ROUNDUP-Apogee Therapeutics, GE Healthcare, Synopsys

Definium Therapeutics Inc : Canaccord Genuity Raises Target Price to $60 From $38

THOMSON REUTERS

Under the Radar: Definium Shares Propelled by Strong Psychedelic Results -- WSJ

Definium Therapeutics posts corporate presentation highlighting DT120 ODT Phase 3 program in GAD and MDD

Small U.S. Stocks Close Mixed As Definium Therapeutics Leads, Butterfly Network Lags

Definium Therapeutics Reports $500 Million Public Offering

MT Newswires Live

Definium Therapeutics offers to sell $500M in common stock

Definium Therapeutics plans USD 500 million follow-on stock offering

Definium Therapeutics, Inc. Announces Proposed Public Offering

THOMSON REUTERS

Definium Therapeutics Is Maintained at Outperform by Leerink Partners

Top Midday Gainers

MT Newswires Live

Canaccord ups Definium Therapeutics target to $60, calls DT120 ‘solid contender’

Definium Therapeutics rises 55.9%

RBC Capital Adjusts Price Target on Definium Therapeutics to $57 From $36, Maintains Outperform Rating

MT Newswires Live

Brisebois Raises Definium Therapeutics Price Target to $63 on Strong DT120 ODT Phase 3 Data and Reduced MDD/GAD Risk

Definium Therapeutics price target raised to $60 from $40 at Oppenheimer

Definium Therapeutics price target raised to $57 from $36 at RBC Capital

Definium Therapeutics Stock (DFTX) Rockets on a Phase 3 Trial Win

RBC Capital says would buy Definium Therapeutics after Phase III data

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/DFTX/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DFTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DFTX\",,,,,undefined,":{"symbol":"DFTX","market":"US","secType":"STK","nameCN":"Definium Therapeutics","latestPrice":38.23,"timestamp":1788363192013,"preClose":38.5,"halted":0,"volume":416425,"delay":0,"changeRate":-0.007012987012987094,"floatShares":131114280,"shares":134366950,"eps":-3.482311,"marketStatus":"Trading","change":-0.27,"latestTime":"09-02 11:33:13 EDT","open":38.5,"high":40.065,"low":38.17,"amount":16222510.4835,"amplitude":0.049221,"askPrice":38.24,"askSize":100,"bidPrice":38.19,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-3.482311,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788379200000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":38.5,"preHourTrading":{"tag":"盘前","latestPrice":38.3,"preClose":38.5,"latestTime":"09:27 EDT","volume":6540,"amount":246819.8616,"timestamp":1788355679328,"change":-0.2,"changeRate":-0.005195,"amplitude":0.037922},"postHourTrading":{"tag":"盘后","latestPrice":38.6,"preClose":38.5,"latestTime":"19:58 EDT","volume":24860,"amount":958344.1953,"timestamp":1788307117321,"change":0.1,"changeRate":0.002597,"amplitude":0.01974},"volumeRatio":0.720791,"impliedVol":1.0626,"impliedVolPercentile":0.6519},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DFTX\",,,,,undefined,":{"symbol":"DFTX","floatShares":131114280,"roa":"-20.64%","roe":"-64.09%","lyrEps":-2.059999,"volumeRatio":0.720791,"shares":134366950,"dividePrice":0,"high":40.065,"amplitude":0.049221,"preClose":38.5,"low":38.17,"week52Low":8.7,"pbRate":"5.59","week52High":49.7,"institutionHeld":0,"latestPrice":38.23,"committee":0.333333,"eps":-3.482311,"divideRate":0,"volume":416425,"delay":0,"ttmEps":-3.482311,"open":38.5,"prevYearClose":13.39,"prevWeekClose":40.98,"prevMonthClose":39.72,"prevQuarterClose":47.04,"fiveDayClose":43.77,"twentyDayClose":44.39,"sixtyDayClose":23.02},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DFTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"DFTX","fiscalQuarterEnding":"2026/06","expectedEps":-0.55,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"post","actualEps":-1.44},{"market":"US","date":"2026-05-07","symbol":"DFTX","fiscalQuarterEnding":"2026/03","expectedEps":-0.47,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"post","actualEps":-0.71},{"market":"US","date":"2026-02-26","symbol":"DFTX","fiscalQuarterEnding":"2025/12","expectedEps":-0.45,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1772082000000,"reportTimeType":"post","actualEps":-0.45}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DFTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DFTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3889,"buy":0.6111,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6111,"analysts":18,"updateTime":1787025600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/DFTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"DFTX","date":"2026-09-01","current":-11.055876,"percent":0.307692,"low":-27.074722,"twenty":-17.384314,"median":-11.106728,"eighty":-9.894411,"high":-8.802064,"avg":-13.907193,"sd":5.5199,"marketCap":5337055254},"quantilePoints":[{"date":"2026-01-16","current":-9.013032,"twenty":-8.970838,"median":-8.907548,"eighty":-8.844258,"marketCap":1515072711},{"date":"2026-01-23","current":-9.944809,"twenty":-9.944809,"median":-9.423248,"eighty":-8.819645,"marketCap":1671702464},{"date":"2026-01-30","current":-10.103035,"twenty":-10.103035,"median":-9.868626,"eighty":-9.013032,"marketCap":1698299969},{"date":"2026-02-06","current":-9.522872,"twenty":-10.196799,"median":-9.918438,"eighty":-9.522872,"marketCap":1600775783},{"date":"2026-02-13","current":-9.511152,"twenty":-10.179218,"median":-9.944809,"eighty":-9.522872,"marketCap":1598805598},{"date":"2026-02-20","current":-10.120616,"twenty":-10.18039,"median":-9.944809,"eighty":-9.520528,"marketCap":1701255248},{"date":"2026-02-27","current":-9.267085,"twenty":-10.187422,"median":-9.96239,"eighty":-9.520528,"marketCap":1703225433},{"date":"2026-03-06","current":-9.519961,"twenty":-10.18039,"median":-9.903787,"eighty":-9.502065,"marketCap":1749702163},{"date":"2026-03-13","current":-9.753213,"twenty":-10.18039,"median":-9.918437,"eighty":-9.518199,"marketCap":1792572359},{"date":"2026-03-20","current":-10.122078,"twenty":-10.169841,"median":-9.903787,"eighty":-9.52229,"marketCap":1860367087},{"date":"2026-03-27","current":-10.273963,"twenty":-10.169841,"median":-9.918437,"eighty":-9.559599,"marketCap":1888282563},{"date":"2026-04-02","current":-11.174427,"twenty":-10.181562,"median":-9.918437,"eighty":-9.550417,"marketCap":2053781457},{"date":"2026-04-10","current":-11.619234,"twenty":-10.247114,"median":-9.944809,"eighty":-9.57529,"marketCap":2135533923},{"date":"2026-04-17","current":-12.18338,"twenty":-10.396104,"median":-9.980506,"eighty":-9.589394,"marketCap":2239219977},{"date":"2026-04-24","current":-12.617338,"twenty":-11.167918,"median":-10.038572,"eighty":-9.618687,"marketCap":2318978480},{"date":"2026-05-01","current":-11.86876,"twenty":-11.389236,"median":-10.10442,"eighty":-9.643639,"marketCap":2181395062},{"date":"2026-05-08","current":-13.767387,"twenty":-11.71579,"median":-10.122078,"eighty":-9.665202,"marketCap":2530349365},{"date":"2026-05-15","current":-9.802755,"twenty":-11.643102,"median":-10.113211,"eighty":-9.689477,"marketCap":2328575817},{"date":"2026-05-22","current":-10.399644,"twenty":-11.570414,"median":-10.105791,"eighty":-9.636028,"marketCap":2470362634},{"date":"2026-05-29","current":-10.780735,"twenty":-11.483622,"median":-10.120616,"eighty":-9.642537,"marketCap":2560888064},{"date":"2026-06-05","current":-11.290386,"twenty":-11.393576,"median":-10.145827,"eighty":-9.660184,"marketCap":2681952193},{"date":"2026-06-12","current":-11.069996,"twenty":-11.344489,"median":-10.179218,"eighty":-9.68473,"marketCap":2629600138},{"date":"2026-06-18","current":-11.216923,"twenty":-11.349156,"median":-10.196799,"eighty":-9.702279,"marketCap":2664501508},{"date":"2026-06-26","current":-20.565124,"twenty":-11.510745,"median":-10.247973,"eighty":-9.723056,"marketCap":4885101210},{"date":"2026-07-02","current":-24.252692,"twenty":-11.77112,"median":-10.299843,"eighty":-9.753213,"marketCap":5761057223},{"date":"2026-07-10","current":-27.074722,"twenty":-12.069466,"median":-10.333633,"eighty":-9.796609,"marketCap":6431410656},{"date":"2026-07-17","current":-24.643864,"twenty":-12.519698,"median":-10.492938,"eighty":-9.802755,"marketCap":5853977501},{"date":"2026-07-24","current":-23.990048,"twenty":-12.931958,"median":-10.537388,"eighty":-9.812883,"marketCap":5698667894},{"date":"2026-07-31","current":-24.861803,"twenty":-14.440728,"median":-10.67054,"eighty":-9.817222,"marketCap":5905747370},{"date":"2026-08-07","current":-17.312135,"twenty":-19.588062,"median":-10.789918,"eighty":-9.824231,"marketCap":6124773739},{"date":"2026-08-14","current":-16.673146,"twenty":-17.887875,"median":-10.831241,"eighty":-9.831914,"marketCap":5898709105},{"date":"2026-08-21","current":-17.242844,"twenty":-17.526933,"median":-11.058518,"eighty":-9.861594,"marketCap":6100259530},{"date":"2026-08-28","current":-16.642763,"twenty":-17.426666,"median":-11.092954,"eighty":-9.887379,"marketCap":5887959749},{"date":"2026-09-01","current":-15.085589,"twenty":-17.384314,"median":-11.106728,"eighty":-9.894411,"marketCap":5337055254}],"updateTime":1788341670804},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DFTX\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2645241838","title":"Definium Therapeutics price target raised to $57 from $37 at Baird","url":"https://stock-news.laohu8.com/highlight/detail?id=2645241838","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645241838?lang=en_us&edition=fundamental","pubTime":"2026-06-23 18:50","pubTimestamp":1782211811,"startTime":"0","endTime":"0","summary":"Baird analyst Christopher Chen raised the firm’s price target on Definium Therapeutics (DFTX) to $57 from $37 and keeps an Outperform rating on the...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-price-target-raised-to-57-from-37-at-baird-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-price-target-raised-to-57-from-37-at-baird-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645852618","title":"U.S. RESEARCH ROUNDUP-Apogee Therapeutics, GE Healthcare, Synopsys","url":"https://stock-news.laohu8.com/highlight/detail?id=2645852618","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645852618?lang=en_us&edition=fundamental","pubTime":"2026-06-23 15:27","pubTimestamp":1782199671,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Apogee Therapeutics, GE Healthcare, Synopsys June 23 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, includi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nL8N42V0CS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVAV","ALGT","APGE","CELT","BPH","DXCM","AVXX","CDW","D","BBWI","CAR","DPZ","BP","ABBV","DFTX","DLLL","AHR","DELL","BEX","BTI","CELH","CNC","DAR","CNCG","ARES","BEG","AAL","E","BEZ","CAT","BNY","CPB","GEHC","ALAB","ANET","LABX","AEIS","CTSH","KMX","APH","ALK","AMAT","BAC","ACN","ALLY","BE","ACLS","DAL","ASH","CHPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645002748","title":"Definium Therapeutics Inc : Canaccord Genuity Raises Target Price to $60 From $38","url":"https://stock-news.laohu8.com/highlight/detail?id=2645002748","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645002748?lang=en_us&edition=fundamental","pubTime":"2026-06-23 11:49","pubTimestamp":1782186572,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nFWN42U04Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645032910","title":"Under the Radar: Definium Shares Propelled by Strong Psychedelic Results -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2645032910","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645032910?lang=en_us&edition=fundamental","pubTime":"2026-06-23 06:40","pubTimestamp":1782168000,"startTime":"0","endTime":"0","summary":"Shares of Definium Therapeutics surged 50% on Monday after the biotech announced that a single dose of its LSD drug significantly eased symptoms of depression in a late-stage trial.The drug, called DT120, beat a placebo by 8.1 points on a 60-point depression scale doctors use to track symptoms, six weeks after a single dose. The benefit held at the three-month mark.DT120 is a pharmaceutically formulated version of LSD that dissolves on the tongue. It is part of a wave of psychedelic drugs-which also include psilocybin and MDMA-that researchers are testing to treat mental-health conditions. President Trump signed an executive order aimed at speeding up research and development for psychedelic drugs in April.Stifel analysts said the results \"exceeded expectations with clear and highly robust efficacy\" in a research note.This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL .","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645303070","title":"Definium Therapeutics posts corporate presentation highlighting DT120 ODT Phase 3 program in GAD and MDD","url":"https://stock-news.laohu8.com/highlight/detail?id=2645303070","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645303070?lang=en_us&edition=fundamental","pubTime":"2026-06-23 04:31","pubTimestamp":1782160272,"startTime":"0","endTime":"0","summary":"Definium highlighted DT120 ODT, a single-dose lysergide therapy, as its lead late-stage program in five Phase 3 studies for GAD, MDD.Emerge Phase 3 topline data in MDD met the primary endpoint; 8.1-point MADRS improvement over placebo at week 6 .Durability signal extended to week 12; 7.3-point MADRS improvement over placebo ; CGI-S improved by 0.9 at day 2 .Safety update showed no serious adverse events in Emerge through week 12; 99% of AEs were mild-to-moderate; no suicidality signal.Balance sheet showed cash, cash equivalents, investments of USD 373.4 million as of March 31, 2026; runway expected into 2028.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this n","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL6zMSc2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645004077","title":"Small U.S. Stocks Close Mixed As Definium Therapeutics Leads, Butterfly Network Lags","url":"https://stock-news.laohu8.com/highlight/detail?id=2645004077","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645004077?lang=en_us&edition=fundamental","pubTime":"2026-06-23 04:20","pubTimestamp":1782159600,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of small-cap companies were mixed Monday, as the Russell 2000 Index added 0.8%, and the S&P Small Cap 600 Index was unchanged.Among companies with a market value of $1 billion to $6.7 billion, Definium Therapeutics Inc. was the best performer during the session, surging 50%, followed by Horizon Quantum Holdings Ltd., which jumped 20%. Oruka Therapeutics Inc. shares jumped 18%, WhiteFiber Inc. jumped 16%, and shares of Baldwin Insurance Group Inc. jumped 16%.Butterfly Network Inc. was the biggest laggard, dropping 18%, followed by shares of Regencell Bioscience Holdings Ltd., which dropped 12%. Shares of Braiin Ltd. dropped 12%, Trulieve Cannabis Corp. shares plunged 9.7%, and WaterBridge Infrastructure LLC tumbled 9.7%.Major stock indexes in the U.S. closed mixed Monday as the Nasdaq Composite Index fell 1.3%. Meanwhile, the S&P 500 Index dropped 0.4%, and the Dow Jones Industrial Average added 0.3%.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645077087","title":"Definium Therapeutics Reports $500 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2645077087","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645077087?lang=en_us&edition=fundamental","pubTime":"2026-06-23 04:19","pubTimestamp":1782159571,"startTime":"0","endTime":"0","summary":"Definium Therapeutics  said late Monday it intends to offer $500 million shares and pre-funded warrants in an underwritten public offering, with underwriters granted a 30-day option to purchase up to $75 million additional shares.Proceeds will be used among others for research and development, and general corporate purposes, the company said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645107083","title":"Definium Therapeutics offers to sell $500M in common stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2645107083","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645107083?lang=en_us&edition=fundamental","pubTime":"2026-06-23 04:18","pubTimestamp":1782159517,"startTime":"0","endTime":"0","summary":"Definium intends to use the net proceeds from this offering for the research and development of its product candidates, preparation activities for ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-offers-to-sell-500m-in-common-stock-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-offers-to-sell-500m-in-common-stock-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645961077","title":"Definium Therapeutics plans USD 500 million follow-on stock offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2645961077","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645961077?lang=en_us&edition=fundamental","pubTime":"2026-06-23 04:01","pubTimestamp":1782158482,"startTime":"0","endTime":"0","summary":"Definium Therapeutics plans an underwritten public offering of USD 500 million in common shares, with pre-funded warrants available to certain investors.Underwriters receive a 30-day option to buy up to an additional USD 75 million of common shares.Proceeds earmarked for R&D, commercialization preparation for DT120 ODT if approved, working capital, general corporate purposes.J.P. Morgan, Jefferies, Leerink Partners, BofA Securities named joint lead bookrunners.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL3cLfCS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0070302665.USD","LU0320765489.SGD","LU1718418525.SGD","LU1267930227.SGD","LU0321505439.SGD","LU2596442595.SGD","LU0320765646.SGD","LU0306807586.USD","LU0417517546.SGD","LU1201861165.SGD","LU0787776722.HKD","LU0052756011.USD","LU0128525689.USD","BK4581","LU0098860793.USD","LU1074936037.SGD","LU1894683264.USD","LU1506573853.SGD","MNSH","LU0170899867.USD","LU0477156797.USD","BK4585","LU0053666078.USD","LU1804176565.USD","IE0002270589.USD","LU0314106906.USD","LU0683600562.USD","IE00B7SZLL34.SGD","LU0130517989.USD","LU2129689431.USD","LU0130518102.USD","LU2133065610.SGD","BAC","DFTX","LU0106831901.USD","IE0001KFT4U8.USD","IE00BZ1G4Q59.USD","IE00B1BXHZ80.USD","LU1035773651.USD","LU0149725797.USD","LU1069347547.HKD","LU0130102774.USD","LU1162221912.USD","LU0130103400.USD","BK4207","LU0208291251.USD","LU0648000940.SGD","LU1791807156.HKD","LU0648001328.SGD","IE00BKVL7J92.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645007798","title":"Definium Therapeutics, Inc. Announces Proposed Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2645007798","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645007798?lang=en_us&edition=fundamental","pubTime":"2026-06-23 04:01","pubTimestamp":1782158460,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUAWSFYZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645071091","title":"Definium Therapeutics Is Maintained at Outperform by Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2645071091","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645071091?lang=en_us&edition=fundamental","pubTime":"2026-06-23 02:10","pubTimestamp":1782151800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/DFTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 22, 2026 14:10 ET (18:10 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645071067","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2645071067","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645071067?lang=en_us&edition=fundamental","pubTime":"2026-06-23 02:07","pubTimestamp":1782151648,"startTime":"0","endTime":"0","summary":"Nexentis Technologies  said Monday its subsidiary, MitoCareX Bio, has entered into an engagement with Boltz, an AI research lab, to accelerate the identification of novel small-molecule scaffolds targeting selected solute carrier proteins of interest to MitoCareX's pipeline.Shares jumped over 200% as trading volume catapulted to over 55 million from a daily average of about 208,000.AbbVie  agreed to acquire Apogee Therapeutics  for $135.11 per share in cash for a total equity value of $10.9 billion, the companies said Monday.Shares of Apogee soared 47%, with intraday trading volume of over 47.1 million against a daily average of about 975,000.Definium Therapeutics  reported positive topline results from a phase 3 Emerge study of DT120 orally disintegrating tablet in major depressive disorder.RBC Capital raised its price target to $57 from $36, while maintaining its outperform rating.Shares surged 52% amid a jump in intraday trading volume to over 16 million from a daily average of roug","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2468319806.SGD","LU0256863902.USD","LU1718418525.SGD","LU0456855351.SGD","LU0545039389.USD","LU0985320562.USD","IE00BBT3K403.USD","LU0868494708.USD","ABBV","LU0553294199.USD","LU1934455863.HKD","LU1551013425.SGD","LU1839511570.USD","BK4566","IE00BFTCPJ56.SGD","IE00BDGV0183.EUR","LU0859254822.USD","LU2089283258.USD","LU1983299246.USD","LU0795875086.SGD","LU0170899867.USD","BK4585","IE000F7OJYX1.SGD","IE00BJJMRZ35.SGD","LU0211328371.USD","LU1291159041.SGD","LU2237443549.SGD","DFTX","LU0708994859.HKD","LU2023251221.USD","LU1162221912.USD","NXTS","LU1934455194.USD","SG9999011175.SGD","APGE","LU0661504455.SGD","LU0868494617.USD","LU1934455277.USD","BK4533","LU2133065610.SGD","IE00B3PB1722.GBP","LU0211327993.USD","IE000SO60NU8.SGD","LU1244550577.SGD","IE00B42XCP33.USD","LU0069063385.USD","IE0000B7K699.USD","LU1074936037.SGD","IE00B4R5TH58.HKD","IE00BSNM7G36.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645074587","title":"Canaccord ups Definium Therapeutics target to $60, calls DT120 ‘solid contender’","url":"https://stock-news.laohu8.com/highlight/detail?id=2645074587","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645074587?lang=en_us&edition=fundamental","pubTime":"2026-06-23 02:05","pubTimestamp":1782151507,"startTime":"0","endTime":"0","summary":"As previously reported, Canaccord raised the firm’s price target on Definium Therapeutics (DFTX) to $60 from $38 and keeps a Buy rating on the shar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/canaccord-ups-definium-therapeutics-target-to-60-calls-dt120-solid-contender-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/canaccord-ups-definium-therapeutics-target-to-60-calls-dt120-solid-contender-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645798160","title":"Definium Therapeutics rises 55.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645798160","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645798160?lang=en_us&edition=fundamental","pubTime":"2026-06-23 00:11","pubTimestamp":1782144688,"startTime":"0","endTime":"0","summary":"Definium Therapeutics (DFTX) is up 55.9%, or $13.68 to $38.16. Published first on TheFly – the ultimate source for real-time, market-moving breakin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-rises-55-9-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-rises-55-9-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645076458","title":"RBC Capital Adjusts Price Target on Definium Therapeutics to $57 From $36, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2645076458","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645076458?lang=en_us&edition=fundamental","pubTime":"2026-06-23 00:01","pubTimestamp":1782144071,"startTime":"0","endTime":"0","summary":"Definium Therapeutics, Inc. (DFTX) has an average rating of buy and mean price target of $42, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645076482","title":"Brisebois Raises Definium Therapeutics Price Target to $63 on Strong DT120 ODT Phase 3 Data and Reduced MDD/GAD Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2645076482","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645076482?lang=en_us&edition=fundamental","pubTime":"2026-06-22 23:55","pubTimestamp":1782143746,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Francois Brisebois has reiterated their bullish stance on DFTX stock, giving a Buy rating today. Francois Brisebois has giv...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/brisebois-raises-definium-therapeutics-price-target-to-63-on-strong-dt120-odt-phase-3-data-and-reduced-mdd-gad-risk-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/brisebois-raises-definium-therapeutics-price-target-to-63-on-strong-dt120-odt-phase-3-data-and-reduced-mdd-gad-risk-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABVC","ODT","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645076141","title":"Definium Therapeutics price target raised to $60 from $40 at Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2645076141","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645076141?lang=en_us&edition=fundamental","pubTime":"2026-06-22 23:41","pubTimestamp":1782142915,"startTime":"0","endTime":"0","summary":"Oppenheimer raised the firm’s price target on Definium Therapeutics (DFTX) to $60 from $40 and keeps an Outperform rating on the shares. Published ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-price-target-raised-to-60-from-40-at-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-price-target-raised-to-60-from-40-at-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX","OPY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645763780","title":"Definium Therapeutics price target raised to $57 from $36 at RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2645763780","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645763780?lang=en_us&edition=fundamental","pubTime":"2026-06-22 23:35","pubTimestamp":1782142507,"startTime":"0","endTime":"0","summary":"Following Definium Therapeutics (DFTX)’ call detailing the Phase 3 results from the Emerge study, RBC Capital raised the firm’s price target to $57...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-price-target-raised-to-57-from-36-at-rbc-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-price-target-raised-to-57-from-36-at-rbc-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645807310","title":"Definium Therapeutics Stock (DFTX) Rockets on a Phase 3 Trial Win","url":"https://stock-news.laohu8.com/highlight/detail?id=2645807310","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645807310?lang=en_us&edition=fundamental","pubTime":"2026-06-22 22:22","pubTimestamp":1782138120,"startTime":"0","endTime":"0","summary":"Definium Therapeutics stock rallied alongside positive results from a Phase 3 clinical trial.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/definium-therapeutics-stock-dftx-rockets-on-a-phase-3-trial-win?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/definium-therapeutics-stock-dftx-rockets-on-a-phase-3-trial-win?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645907850","title":"RBC Capital says would buy Definium Therapeutics after Phase III data","url":"https://stock-news.laohu8.com/highlight/detail?id=2645907850","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645907850?lang=en_us&edition=fundamental","pubTime":"2026-06-22 21:56","pubTimestamp":1782136590,"startTime":"0","endTime":"0","summary":"Definium Therapeutics (DFTX) reported that the Phase III EMERGE trial for DT120-ODT in major depressive disorder met all primary and secondary endp...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rbc-capital-says-would-buy-definium-therapeutics-after-phase-iii-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rbc-capital-says-would-buy-definium-therapeutics-after-phase-iii-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0708994859.HKD","LU1267930573.SGD","III","DFTX","BK4134","BK4007","LU0029864427.USD","BK4207","LU0310800379.SGD","LU0128525929.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":200,"code":"91000000","status":"200"}]}}